The most common adverse reactions (≥20%) with Tucatinib in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.
The most common adverse reactions (≥20%) with Tucatinib in combination with trastuzumab in patients with unresectable or metastatic colorectal cancer are diarrhea, fatigue, rash, nausea, abdominal pain, infusion related reactions, and pyrexia.
from FDA,2023.01
Common side effects of Tucatinib and management suggestionsLike other medication···【more】
Release date:2026-05-26Recommended:84
Common Side Effects of Tucatinib and Their ManagementIn clinical studies, nearly···【more】
Release date:2026-05-25Recommended:92